Mr. Bloch has served as the Company’s Chief Executive Officer since March 2013, and was previously the company’s Chief Financial Officer. Mr. Bloch is a Chartered Accountant with a track record of building both public and private technology companies, mainly in the Life Sciences industry. His past 25 years of executive management experience includes CFO and Joint Interim CEO of Sanofi Canada Inc., CFO of Intellivax and Founder of Tribute Pharmaceuticals. Mr. Bloch also served as CFO of Gennum and Just Energy, both TSX listed Companies. These companies have ranged in size from start-ups to revenues of over $2 billion. In these roles Mr. Bloch has secured significant funding for both private and public companies, including experience with Initial Public Offerings. Mr. Bloch has been on a number of both public and private company’s board of directors.

Bob Hariri is a surgeon, biomedical scientist and highly successful serial entrepreneur in two technology sectors: biomedicine and aerospace. Dr. Hariri is the Chairman, Founder, Chief Scientific Officer, and former Chief Executive Officer of Celgene Cellular Therapeutics, one of the world’s largest human cellular therapeutics companies. Dr. Hariri has pioneered the use of stem cells to treat a range of life threatening diseases and has made transformative contributions in the field of tissue engineering.

His activities and experience includes academic neurosurgeon at Cornell, businessman, military surgeon and aviator and aerospace innovator. Dr. Hariri has over 90 issued and pending patents, has authored over 100 published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the placenta and as a member of the team which discovered the physiological activities of TNF (tumor necrosis factor).

Dr. Hariri was recipient of the Thomas Alva Edison Award in 2007 and 2011, The Fred J. Epstein Lifetime Achievement Award and has received numerous other honors for his many contributions to biomedicine and aviation. Dr. Hariri also serves on numerous Boards of Directors including MYOS Corporation and Provista Diagnostics. Dr. Hariri is an Adjunct Associate Professor of Pathology at the Mount Sinai School of Medicine and a member of the Board of Visitors of the Columbia University School of Engineering & Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons, and is a member of the scientific advisory board for the Archon X PRIZE for Genomics, which is awarded by the X PRIZE Foundation. Dr. Hariri is also a Trustee of the Liberty Science Center and has been appointed Commissioner of Cancer Research by New Jersey Governor Christie. Dr. Hariri is a member of the Board of Trustees of the J. Craig Venter Institute.

Dr. Hariri is a jet-rated commercial pilot with thousands of hours of flight time in over 60 different military and civilian aircraft Dr. Hariri has also produced several feature films as well as documentaries on global societal issues.

Mr. Mathieu has been the U.S. Chief Marketing Officer of Samsung North America since June 2015. Prior to that, from April 2011 to June 2015, he was Senior Vice President of Global Marketing at Unilever, where he was responsible for the development of Unilever’s global marketing strategy. Mr. Mathieu has also overseen the implementation of pivotal programs such as Project Sunlight, the first Unilever brand consumer initiative to motivate millions of people to adopt more sustainable lifestyles, and The Unilever Foundry, a platform that provides a single entry-point for innovative start-ups seeking to partner with Unilever. Since January 2011, Mr. Mathieu has been the Chairman and Co-founder of We&Co, a social app for people who provide and enjoy great service. From January 2009 through August 2011, Mr. Mathieu founded and was principal of the strategic brand consultancy, BeDo, which worked to build brands with purpose and fuse marketing and sustainability agendas. From 1996 through 2008, Mr. Mathieu held various positions at Coca-Cola, culminating in Senior Vice President Global Brand Marketing. He sits on the Advisory Panel of the Guardian Digital and Media network and writes for Marketing Week magazine. He is a regular conference and keynote speaker on themes such as the Future of Marketing. Mr. Mathieu has a passion for theatre and sits on the Board of Directors for the Almeida Theatre and Punchdrunk.

Mr. Prywata is the co-founder of Bionik Laboratories and has served as the company’s Chief Operating Officer since March 2013, and was previously the company’s Chief Executive Officer. He studied biomedical engineering at Ryerson University and has a proven track record of inventing and winning technology showcases. While attending Ryerson, Mr. Prywata co-invented the world’s first robotic, prosthetic arm that is controlled by brain signals. Equally impressive is his strong understanding of developing technologies that address significant and untapped markets. He is responsible for raising the initial capital to found Bionik and turn numerous concepts into products.

Dr. Krebs joined Bionik during the acquisition of Interactive Motion Technologies and has served as the Company's Chief Science Officer since April 2016. Prior to joining Bionik, Dr. Krebs was the Co-Founder and Chairman of the Board of Directors of Interactive Motion Technologies. Dr. Krebs is a Principal Research Scientist and Lecturer at the Massachusetts Institute of Technology, Newman Laboratory for Biomechanics and Human Rehabilitation. He also holds affiliate positions as an Adjunct Professor at University of Maryland School of Medicine, Department of Neurology and in the Division of Rehabilitative Medicine, as a Visiting Professor at Fujita Health University, Department of Physical Medicine and Rehabilitation, Japan, as a Visiting Professor at Newcastle University, Institute of Neuroscience, UK, and as a Visiting Professor at Osaka University, Department of Mechanical Engineering, Japan.

Dr. Krebs is a pioneer in the design, development, clinical use, and research of robots used to administer rehabilitation therapy to patients with neurological injury, and was recognized as such with the prestigious Institute of Electrical and Electronics Engineers (IEEE) INABA Technical Award for Innovation leading to Production in 2015. This award recognizes original innovative research and concepts that have evolved into commercialized products. In 2014, Dr. Krebs was nominated as Fellow of the IEEE for his contributions to rehabilitation robotics and the understanding of neuro-rehabilitation.

Dr. Krebs holds numerous foundational patents for the use of robotic technology in rehabilitation and has been published in more than 200 peer-reviewed scientific and clinical publications.